Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

Transarterial radioembolization (TARE) is an emerging treatment for patients with unresectable hepatocellular carcinoma (HCC). This study successfully developed radiometal-labeled chitosan microspheres (<sup>111</sup>In/<sup>177</sup>Lu-DTPA-CMS) with a diameter of 36.5 ± 5.3...

Full description

Bibliographic Details
Main Authors:	Hui-Wen Chan, Yi-Hsuan Lo, Deng-Yuan Chang, Jia-Je Li, Wen-Yi Chang, Chih-Hao Chen, Chih-Hsien Chang, Chuan-Lin Chen, Hsin-Ell Wang, Ren-Shyan Liu, Chun-Yi Wu
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Gels
Subjects:	transarterial radioembolization (TARE) hepatocellular carcinoma (HCC) radiolabeled chitosan microspheres (<sup>111</sup>In/<sup>177</sup>Lu-DTPA-CMS) theranostics
Online Access:	https://www.mdpi.com/2310-2861/8/3/180

Similar Items

Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties
by: Ana Cláudia Camargo Miranda, et al.
Published: (2021-06-01)

PSMA Theranostics: Science and Practice
by: Kgomotso Mokoala, et al.
Published: (2021-08-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agent for Colon Cancer
by: Radu Anton Leonte, et al.
Published: (2021-04-01)

Brachytherapy Approach Using <sup>177</sup>Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model
by: Min-Ying Lin, et al.
Published: (2021-11-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022-10-01)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Rosalba Mansi, et al.
Published: (2021-12-01)

Predictive Value of [<sup>99m</sup>Tc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [<sup>90</sup>Y]-TARE: A Single-Center Experience
by: Michael Doppler, et al.
Published: (2023-07-01)

<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
by: Kim N. Chi, et al.
Published: (2024-03-01)

<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans
by: Licia Uccelli, et al.
Published: (2021-09-01)

Transarterial radioembolization: a systematic review on gaining control over the parameters that influence microsphere distribution
by: T. J. Snoeijink, et al.
Published: (2023-12-01)

Peptide Receptor Radionuclide Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
by: Maria I. del Olmo-García, et al.
Published: (2022-01-01)

<sup>188</sup>Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study)
by: Etienne Garin, et al.
Published: (2023-04-01)

Radioembolization for the treatment of hepatocellular carcinoma
by: Hyo-Cheol Kim
Published: (2017-06-01)

Quality Assurance Investigations and Impurity Characterization during Upscaling of [<sup>177</sup>Lu]Lu-PSMA<sup>I&T</sup>
by: Stefan Schmitl, et al.
Published: (2023-11-01)

Biomarkers in Prostate-Specific Membrane Antigen Theranostics
by: Panagiotis J. Vlachostergios, et al.
Published: (2021-06-01)

Preclinical Characterization of the <sup>177</sup>Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5
by: Franziska Striese, et al.
Published: (2023-05-01)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022-08-01)

Optimized Therapeutic <sup>177</sup>Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-12-01)

Synthesis, Characterization, and Therapeutic Efficacy of <sup>177</sup>Lu-DMSA@SPIONs in Nanobrachytherapy of Solid Tumors
by: Dragana Stanković, et al.
Published: (2023-07-01)

Radioactivity distribution in the blood and urine of patients receiving systemic therapy with a <sup>177</sup>Lu radiopharmaceutical and local (intra-articular) therapy with a <sup>188</sup>Re radiopharmaceutical
by: E. D. Stepchenkova, et al.
Published: (2022-12-01)

Safety and Efficacy of <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing <sup>223</sup>Radium-Dichloride
by: Justus Baumgarten, et al.
Published: (2022-01-01)

Radioembolization for hepatocellular carcinoma: what clinicians need to know
by: Jin Woo Choi, et al.
Published: (2022-03-01)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi and [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>
by: Sanjana Ballal, et al.
Published: (2021-11-01)

Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects
by: Philippe d’Abadie, et al.
Published: (2021-06-01)

Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
by: Ulrika Jahn, et al.
Published: (2021-02-01)

Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients
by: Sung Won Chung, et al.
Published: (2023-02-01)

Evaluation of Radioiodinated Fluoronicotinamide/Fluoropicolinamide-Benzamide Derivatives as Theranostic Agents for Melanoma
by: Chao-Cheng Chen, et al.
Published: (2020-09-01)

Production and Quality Control of [<sup>177</sup>Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials
by: Valentina Di Iorio, et al.
Published: (2022-06-01)

Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer
by: Robert Drescher, et al.
Published: (2023-06-01)

Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [<sup>177</sup>Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model
by: Judith Anna Delage, et al.
Published: (2021-01-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [<sup>177</sup>Lu]Lu-PSMA I&T
by: Philipp E. Hartrampf, et al.
Published: (2022-01-01)

Radiochemical Feasibility of Mixing of <sup>99m</sup>Tc-MAA and <sup>90</sup>Y-Microspheres with Omnipaque Contrast
by: Chang-Tong Yang, et al.
Published: (2022-11-01)

Toxicity Assessment of [<sup>177</sup>Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
by: Tania Hernández-Jiménez, et al.
Published: (2022-11-01)

RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by: Marie Terroir, et al.
Published: (2023-05-01)

In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor
by: Christopher Montemagno, et al.
Published: (2021-03-01)

Long-Term Survival and Value of <sup>18</sup>F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with <sup>177</sup>Lu-DOTATATE
by: Margarida Rodrigues, et al.
Published: (2021-03-01)

[<sup>68</sup>Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [<sup>177</sup>Lu]DOTATOC PRRT: The “Theragnomics” Concept
by: Riccardo Laudicella, et al.
Published: (2022-02-01)

<sup>177</sup>Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials
by: Alberto Bongiovanni, et al.
Published: (2022-12-01)